title: [Cost-effective PET scans in oncology].
abstract: The authors have reviewed the financial considerations of oncological FDG PET examinations by the guidelines of the Health Care Financing Administration (USA). By critical assessment of large number of clinical investigations, the cost-effectiveness of FDG PET scans has been confirmed in the following cases: differential diagnosis of solitary pulmonary nodule, diagnosis, staging and restaging of non-small cell lung cancer, colorectal cancer, malignant lymphomas, melanoma malignum, esophageal neoplasms and cancers of the head and neck. The role of this method in breast cancer is currently under intensive investigation. Due to the correct staging, PET examinations in these indications enable the clinicians to choose the optimal treatment ensuring the maximum probability of recovery and being cost-effective as unnecessary medical interventions become avoidable.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, PET Centrum, Debrecen. kalvin@pet.dote.hu
authors.forename: Beáta
authors.initials: B
authors.lastname: Kálvin
authors.forename: Attila
authors.initials: A
authors.lastname: Fekésházy
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Lengyel
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Szakáll
authors.forename: Péter
authors.initials: P
authors.lastname: Agoston
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Lengyel
authors.forename: Judit
authors.initials: J
authors.lastname: Székely
authors.forename: Erika
authors.initials: E
authors.lastname: Várady
authors.forename: László
authors.initials: L
authors.lastname: Galuska
authors.forename: Lajos
authors.initials: L
authors.lastname: Trón
authors.forename: Olga
authors.initials: O
authors.lastname: Esik
mesh_terms: D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging; D003362:Cost-Benefit Analysis; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging; D005260:Female; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D006814:Hungary; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008223:Lymphoma / Q000000981:diagnostic imaging; D006278:Medicare; D008545:Melanoma / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics*; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000191:economics* / Q000379:methods; D014481:United States
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18